2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France

被引：31

作者：

Franchet, Camille ^{[1
]}

Djerroudi, Lounes ^{[1
]}

Maran-Gonzalez, Aurelie ^{[1
]}

Abramovici, Olivia ^{[1
]}

Antoine, Martine ^{[1
]}

Becette, Veronique ^{[1
]}

Berghian, Anca ^{[1
]}

Blanc-Fournier, Cecile ^{[1
]}

Brabencova, Eva ^{[1
]}

Charafe-Jauffret, Emmanuelle ^{[1
]}

Chenard, Marie-Pierre ^{[1
]}

Dauplat, Marie-Melanie ^{[1
]}

Delree, Paul ^{[1
]}

Duprez-Paumier, Raphaelle ^{[1
]}

Fleury, Clemence ^{[1
]}

Ghnassia, Jean-Pierre ^{[1
]}

Haudebourg, Juliette ^{[1
]}

Leroux, Agnes ^{[1
]}

MacGrogan, Gaetan ^{[1
]}

Mathieu, Marie-Christine ^{[1
]}

Michenet, Patrick ^{[1
]}

Penault-Llorca, Frederique ^{[1
]}

Poulet, Bruno ^{[1
]}

Robin, Yves Marie ^{[1
]}

Roger, Pascal ^{[1
]}

Russ, Elisabeth ^{[1
]}

Tixier, Lucie ^{[1
]}

Treilleux, Isabelle ^{[1
]}

Valent, Alexander ^{[1
]}

Verriele, Veronique ^{[1
]}

Vincent-Salomon, Anne ^{[1
]}

Arnould, Laurent ^{[1
]}

Lacroix-Triki, Magali ^{[1
]}

机构：

[1] Grp Etud Facteurs Pronost Immunohistochim Canc Se, Unicanc, 101 Rue Tolbiac, F-75654 Paris 13, France

来源：

ANNALES DE PATHOLOGIE | 2021年 / 41卷 / 06期

关键词：

Breast cancer; Guidelines; HER2; Immunohistochemistry; In situ hybridization; ERBB2; PATHOLOGICAL COMPLETE RESPONSE; IN-SITU HYBRIDIZATION; FACTOR RECEPTOR 2; GENE AMPLIFICATION; ADJUVANT TRASTUZUMAB; ESTROGEN-RECEPTOR; OPEN-LABEL; MULTICENTER; EXPRESSION; MUTATIONS;

D O I：

10.1016/j.annpat.2021.07.014

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

The last international guidelines on HER2 determination in breast cancer have been updated in 2018 by the American Society of Clinical Oncology and College of American Pathologists, on the basis of a twenty-year practice and results of numerous clinical trials. Moreover, the emerging HER2-low concept for 1+ and 2+ non amplified breast cancers lead to refine French practices for HER2 status assessment. The GEFPICS group, composed of expert pathologists, herein presents the latest French recommendations for HER2 status evaluation in breast cancer, taking into account the ASCO/CAP guidelines and introducing the HER2-low concept. In the era of personalized medicine, HER2 status assessment remains one of the most important biomarkers in breast cancer and its quality guaranties the optimal patients' care. French pathologists' commitment in theranostic biomarker quality is more than ever required to provide the most efficient cares in oncology. (C) 2021 Elsevier Masson SAS. All rights reserved.

引用

页码：507 / 520

页数：14

共 50 条

[21] Quantification of HER2/HER3 Dimerisation Status in Primary Invasive Breast Cancer
Barros, F. F. T.
Abdel-Fatah, T. M. A.
Rakha, E. A.
Chan, S.
Green, A. R.
Ellis, I. O.
JOURNAL OF PATHOLOGY, 2012, 228 : S14 - S14
[22] HER2 status in bilateral breast cancer
Crowe, Joseph P.
Patrick, Rebecca J.
Rybicki, Lisa A.
Budd, G. Thomas
Escobar, Pedro F.
Tubbs, Raymond R.
Hicks, David G.
INTERNATIONAL JOURNAL OF FERTILITY AND WOMENS MEDICINE, 2006, 51 (05) : 219 - 223
[23] Assessment of HER-2 status in invasive breast cancer in Brazil
Arrua Arias, Victor Eduardo
Gobbi, Helenice
Ioshii, Sergio Ossamu
Scapulatempo, Cristovam
da Paz, Alexandre Rolim
da Silva, Vinicius Duval
Uchoa, Diego
Zettler, Claudio
Soares, Fernando Augusto
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2017, 63 (07): : 566 - 574
[24] Correlation of HER2 gene and chromosome 17 status with pathologic factors in her2 2+ invasive breast cancer
MacGrogan, G.
Chibon, F.
de Mascarel, I.
Sierankowski, G.
Brouste, V.
MODERN PATHOLOGY, 2007, 20 : 40A - 40A
[25] Correlation of HER2 gene and chromosome 17 status with pathologic factors in her2 2+ invasive breast cancer
MacGrogan, G.
Chibon, F.
de Mascarel, I.
Sierankowski, G.
Brouste, V.
LABORATORY INVESTIGATION, 2007, 87 : 40A - 40A
[26] Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France
MacGrogan, Gaetan
Mathieu, Marie-Christine
Poulet, Bruno
Penault-Llorca, Frederique
Vincent-Salomon, Anne
Roger, Pascal
Treilleux, Isabelle
Valent, Alexander
Antoine, Martine
Becette, Veronique
Bor, Catherine
Brabencova, Eva
Charafe-Jauffret, Emmanuelle
Chenard, Marie-Pierre
Dauplat, Marie-Melanie
Delree, Paul
Devouassoux, Mojgan
Fiche, Maryse
Fondrevelle, Marie-Eve
Fridman, Viviana
Garbar, Christian
Genin, Pascal
Ghnassia, Jean-Pierre
Haudebourg, Juliette
Laberge-Le Couteulx, Sophie
Loussouarn, Delphine
Maran-Gonzalez, Aurelie
Marcy, Myriam
Michenet, Patrick
Sagan, Christine
Trassard, Martine
Verriele, Veronique
Arnould, Laurent
Lacroix-Triki, Magali
ANNALES DE PATHOLOGIE, 2014, 34 (05) : 366 - 372
[27] Assessment of HER2 using the 2018 ASCO/CAP guideline update for invasive breast cancer: a critical look at cases classified as HER2 2+ by immunohistochemistry
Valerie J. Taylor
Penny J. Barnes
Sean C. Godwin
Gillian C. Bethune
Virchows Archiv, 2021, 479 : 23 - 31
[28] Assessment of HER2 using the 2018 ASCO/CAP guideline update for invasive breast cancer: a critical look at cases classified as HER2 2+by immunohistochemistry
Taylor, Valerie J.
Barnes, Penny J.
Godwin, Sean C.
Bethune, Gillian C.
VIRCHOWS ARCHIV, 2021, 479 (01) : 23 - 31
[29] Assessment of hormonal receptor immunoexpression and Her2 status in invasive breast cancer after conservative and radical surgery
Tenea-Cojan, Tiberiu Stefanita
Macovei, Adrian
Paun, Ion
Costin, Andrei Ionut
Georgescu, Claudia-Valentina
Georgescu, Corneliu Cristian
Vladu, Ionela Mihaela
Ene, Cristina Gabriela
Radu, Lucretiu
ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2018, 59 (03): : 763 - 772
[30] HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
Sasagu Kurozumi
Mary Padilla
Masafumi Kurosumi
Hiroshi Matsumoto
Kenichi Inoue
Jun Horiguchi
Izumi Takeyoshi
Tetsunari Oyama
Jim Ranger-Moore
D. Craig Allred
Eslie Dennis
Hiroaki Nitta
Breast Cancer Research and Treatment, 2016, 158 : 99 - 111

← 1 2 3 4 5 →